Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$74.20 ▲ +2.15
(+2.98%)
MKT CAP: $3.66B • VOL: 458.4K
52W L $54 52W H $92
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$62
MEDIAN
$83
MEAN
$85
HIGH
$101
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TARS TAPE
TARS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $89.78 | $85.33 | 2025-02-14 | $67.52 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $93.49 | $87.56 | 2025-02-06 | $69.75 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $84.59 | $81.62 | 2025-01-29 | $71.23 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $75.68 | — | 2025-01-17 | $72.72 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $65.30 | $70.49 | 2025-01-09 | $66.04 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $88.30 | $77.17 | 2024-12-18 | $64.55 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $71.97 | $74.94 | 2024-12-04 | $69.01 | -4.3% | 48% | C |